A Mayo Clinic-led cooperative group trial found that extending lenalidomide maintenance beyond two years did not improve overall survival in standard-risk multiple myeloma, challenging the practice of indefinite therapy. The study coordinated by Mayo researchers addresses a decision point clinicians have faced: whether “continuous” maintenance meaningfully changes long-term outcomes. The results arrive as other randomized evidence continues to test optimal duration strategies for lenalidomide and related regimens, with trial design focused on balancing survival benefit against ongoing treatment burden and toxicity. For the industry, the data sharpen payer and provider discussions around real-world duration, especially as maintenance endpoints increasingly intersect with biomarker response and treatment de-escalation approaches.